General Updates4 Nov 2026 · 12:06
Dr. Reddy's Laboratories Limited has informed the Exchange about allotment of Employee stock options
Markets / Nifty 50 / Healthcare
Price
Daily closing prices, adjusted for bonuses and splits
Returns against the Nifty 50
| Return | 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|
| DRREDDY | +2.9% | +14.2% | +16.8% | +4.8% | +14.5% | +30.5% | +44.1% |
| Nifty 50 | +5.6% | +6.2% | −2.7% | −1.5% | −6.4% | +24.6% | +33.7% |
Price returns, without dividends. Source: NSE end-of-day data.
Check-up
Where DRREDDY sits against the Nifty 50 and its industry. Facts, not advice.
Price return
+14.50%
Over 1 year. The Nifty 50 returned −6.40%, so DRREDDY beat it by 20.9 percentage points.
Valuation (PE)
41.0
Price is 41.0 times the last four quarters' earnings per share, higher than the Nifty 50's PE of 19.8 and the 4 industry peers' median of 47.1.
Growth
−1.5%
Revenue in Q2 FY27 compared with the same quarter a year earlier. Net profit changed −31.3%.
Profitability (ROE)
7.2%
Profit over the last four quarters as a share of shareholders' equity. Net margin is 8.5%.
Debt
0.15×
Borrowings are 0.15 times shareholders' equity (latest balance sheet, 30 Sep 2026).
Volatility
1.78×
Daily price moves over the last year were 1.78 times as large as the Nifty 50's (annualised volatility 24.7%).
What the latest numbers show
Calculated by stockER from the company's filings and NSE data.
Positives 3
- Operating cash flow of ₹5,674 crCash generated by the business in the year to 31 Mar 2026.
- Mutual fund holding up 0.83 points in a year14.14% on 30 Sep 2026, from 13.31%.
- Trading near its 52-week highClosed at ₹1,374.00, within 3% of the high of ₹1,414.90 on 29 Jun 2026.
Watch points 5
- Revenue down 1.5% from a year ago₹8,698 cr in Q2 FY27, against ₹8,828 cr in Q2 FY26.
- Net profit down 31.7% from a year ago₹913 cr in Q2 FY27, against ₹1,337 cr in Q2 FY26.
- Net margin narrowed to 10.5%From 15.1% in Q2 FY26.
- Borrowings rose 29.6% in a year₹5,826 cr on 30 Sep 2026, against ₹4,496 cr a year earlier.
- Foreign institutional holding down 4.13 points in a year31.39% on 30 Sep 2026, from 35.52%.
Financials
Consolidated results as filed with NSE. ₹ crore unless stated.
Revenue
Net profit
EPS (₹)
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | 8,698 |
| Other income | 150 | 522 | 290 | 324 | 269 | 475 | 355 | 156 |
| Total expenses | 6,661 | 7,051 | 6,958 | 7,414 | 7,481 | 7,827 | 7,902 | 7,619 |
| EBITDA | 2,423 | 2,520 | 2,464 | 2,334 | 2,156 | 858 | 1,215 | 1,887 |
| Depreciation | 471 | 455 | 476 | 505 | 521 | 557 | 537 | 527 |
| Finance cost | 82 | 66 | 83 | 91 | 94 | 106 | 126 | 125 |
| PBIT | 1,952 | 2,065 | 1,988 | 1,829 | 1,635 | 301 | 678 | 1,360 |
| Profit before tax | 1,870 | 2,000 | 1,905 | 1,738 | 1,541 | 195 | 552 | 1,235 |
| Tax | 470 | 418 | 495 | 408 | 354 | −22 | 118 | 314 |
| Net profit | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | 913 |
| EPS (₹) | 16.97 | 19.12 | 17.04 | 16.18 | 14.53 | 2.65 | 5.33 | 11.10 |
| ₹ crore | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue from operations | 24,670 | 28,011 | 32,644 | 33,700 |
| Other income | 1,092 | 903 | 1,167 | 1,358 |
| Total expenses | 19,750 | 21,728 | 26,153 | 29,679 |
| EBITDA | 7,404 | 8,827 | 9,644 | 7,812 |
| Depreciation | 1,250 | 1,470 | 1,704 | 2,059 |
| Finance cost | 143 | 171 | 283 | 374 |
| PBIT | 6,154 | 7,357 | 7,941 | 5,753 |
| Profit before tax | 6,011 | 7,186 | 7,658 | 5,379 |
| Tax | 1,541 | 1,623 | 1,954 | 1,235 |
| Net profit | 4,507 | 5,578 | 5,725 | 4,158 |
| ₹ crore | MAR 2024 | SEP 2024 | MAR 2025 | SEP 2025 | MAR 2026 | SEP 2026 |
|---|---|---|---|---|---|---|
| Total assets | 38,864 | 46,728 | 49,427 | 54,373 | 58,123 | 57,631 |
| Current assets | 24,805 | 25,048 | 25,018 | 27,956 | 30,179 | 29,732 |
| Inventories | 6,355 | 7,204 | 7,108 | 7,582 | 7,653 | 8,118 |
| Cash and equivalents | 711 | 1,133 | 1,465 | 991 | 1,537 | 1,329 |
| Total liabilities | 10,609 | 15,585 | 15,499 | 18,000 | 19,892 | 18,505 |
| Current liabilities | 9,588 | 12,921 | 13,034 | 15,104 | 16,747 | 15,430 |
| Borrowings | 1,652 | 4,382 | 4,184 | 4,496 | 6,294 | 5,826 |
| Shareholders' equity | 28,255 | 31,143 | 33,927 | 36,373 | 38,231 | 39,126 |
| Equity attributable to owners | 28,255 | 30,749 | 33,550 | 36,014 | 37,892 | 38,807 |
Balance sheets are filed every half year (September and March).
| ₹ crore | 6M to SEP 2022 | 12M to MAR 2025 | 6M to SEP 2025 | 12M to MAR 2026 | 6M to SEP 2026 |
|---|---|---|---|---|---|
| From operations | 1,594 | 4,643 | 3,020 | 5,674 | 435 |
| From investing | 81 | −5,102 | −2,874 | −6,549 | 812 |
| From financing | −2,315 | 1,186 | −653 | 829 | −1,469 |
| Capital expenditure | 582 | 2,750 | 1,209 | 2,331 | 582 |
| Free cash flow | 1,012 | 1,892 | 1,812 | 3,343 | −147 |
Cash flow statements are filed every half year; figures are for the period shown.
EBITDA here is profit before tax plus finance cost and depreciation. Annual figures add up the four quarters of each financial year. Source: company filings on NSE (XBRL).
Peers
Healthcare companies in the Nifty 50.
| Company | Price | Market cap | PE | PB | ROE | Div. yield | 1Y return |
|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd.DRREDDY | ₹1,374.00 | ₹1.15 lakh cr | 41.0 | 2.96 | 7.2% | 0.58% | +14.5% |
| Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹1,773.40 | ₹4.25 lakh cr | 38.8 | 4.77 | 12.3% | 0.90% | +4.9% |
| Apollo Hospitals Enterprise Ltd.APOLLOHOSP | ₹8,599.50 | ₹1.24 lakh cr | 55.1 | 11.66 | 21.1% | 0.23% | +10.1% |
| Cipla Ltd.CIPLA | ₹1,402.00 | ₹1.13 lakh cr | 39.1 | 3.20 | 8.2% | 0.93% | −6.7% |
| Max Healthcare Institute Ltd.MAXHEALTH | ₹927.15 | ₹90,240 cr | 65.4 | 7.96 | 12.2% | 0.22% | −18.6% |
Price comparison
Change in price from the start of the period
DRREDDYNifty 50SUNPHARMAAPOLLOHOSP
Events
Dividends, bonuses and splits from NSE's corporate actions.
Dividend paid in 5 of the last 5 calendar years (2022–2026)Over the last 12 months: ₹8.00 per share (adjusted for bonuses and splits), a yield of 0.58% at today's price.
Past dividends
Dividend
Dividend - Rs 8 Per SharePer share
₹8.00Ex-date
10 Jul 2026
Dividend - Rs 8 Per SharePer share
₹8.00Ex-date
10 Jul 2026
Dividend
Dividend - Rs 8 Per SharePer share
₹8.00Ex-date
10 Jul 2025
Dividend - Rs 8 Per SharePer share
₹8.00Ex-date
10 Jul 2025
Dividend
Annual General Meeting/Dividend - Rs 40 Per SharePer share
₹40.00Ex-date
16 Jul 2024
Annual General Meeting/Dividend - Rs 40 Per SharePer share
₹40.00Ex-date
16 Jul 2024
Dividend
Annual General Meeting/Dividend - Rs 40 Per SharePer share
₹40.00Ex-date
11 Jul 2023
Annual General Meeting/Dividend - Rs 40 Per SharePer share
₹40.00Ex-date
11 Jul 2023
Dividend
Annual General Meeting/Dividend - Rs 30 Per SharePer share
₹30.00Ex-date
11 Jul 2022
Annual General Meeting/Dividend - Rs 30 Per SharePer share
₹30.00Ex-date
11 Jul 2022
Dividend
Annual General Meeting/Dividend - Rs 25 Per SharePer share
₹25.00Ex-date
9 Jul 2021
Annual General Meeting/Dividend - Rs 25 Per SharePer share
₹25.00Ex-date
9 Jul 2021
Dividend
Annual General Meeting/Dividend - Rs 25 Per SharePer share
₹25.00Ex-date
13 Jul 2020
Annual General Meeting/Dividend - Rs 25 Per SharePer share
₹25.00Ex-date
13 Jul 2020
Dividend
Annual General Meeting/Dividend - Rs 20 Per SharePer share
₹20.00Ex-date
15 Jul 2019
Annual General Meeting/Dividend - Rs 20 Per SharePer share
₹20.00Ex-date
15 Jul 2019
Bonuses, splits and other actions
Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per ShareEx-date
28 Oct 2024
28 Oct 2024
Scheme Of Arrangement - Bonus Debentures 6:1Ex-date
17 Mar 2011
17 Mar 2011
Agm/Div-Rs.6.25 Per ShareEx-date
3 Jul 2009
3 Jul 2009
Filings and updates
The company's own announcements to NSE: results, dividends, presentations and board decisions.
Annual report 2025–26Open (PDF / ZIP)
Annual report 2024–25Open (PDF / ZIP)
Annual report 2023–24Open (PDF / ZIP)
Annual report 2022–23Open (PDF / ZIP)
Annual report 2021–22Open (PDF / ZIP)
Analysts/Institutional Investor Meet/Con. Call Updates29 Oct 2026 · 22:55
Dr. Reddy's Laboratories Limited has informed the Exchange about Transcript
Analysts/Institutional Investor Meet/Con. Call Updates24 Oct 2026 · 11:22
Dr. Reddy's Laboratories Limited has informed the Exchange about Link of Recording
Outcome of Board Meeting23 Oct 2026 · 18:41
Dr. Reddy's Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on October 23, 2026.
Investor Presentation23 Oct 2026 · 17:38
Dr. Reddy's Laboratories Limited has informed the Exchange about Investor Presentation
Outcome of Board Meeting23 Oct 2026 · 17:29
Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Press Release21 Oct 2026 · 09:44
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".
Press Release7 Oct 2026 · 14:41
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".
Analysts/Institutional Investor Meet/Con. Call Updates21 Sep 2026 · 16:50
Dr. Reddy's Laboratories Limited has informed the Exchange about Schedule of meet
General Updates10 Sep 2026 · 17:40
Dr. Reddy's Laboratories Limited has informed the Exchange about Allotment of Employee Stock options
General Updates26 Aug 2026 · 16:12
Dr. Reddy's Laboratories Limited has informed the Exchange about Allotment of employee stock options
Resignation of Director/KMP/SMP13 Aug 2026 · 17:19
Dr. Reddy's Laboratories Limited has informed the Exchange about Resignation of Director/KMP/SMP
Frequently asked questions
What is the share price of Dr. Reddy's Laboratories Ltd. (DRREDDY)?
DRREDDY closed at ₹1,374.00 on NSE on 4 Nov 2026, +0.42% on the day. stockER shows end-of-day prices, updated after the market closes.
What is the market cap of DRREDDY?
₹1.15 lakh cr, based on 83.47 crore shares and the latest closing price. That makes it #46 by size in the Nifty 50.
What are the PE and PB ratios of DRREDDY?
PE 40.96 on earnings per share of ₹33.54 over the last four quarters; PB 2.96 on the latest reported equity.
What is the 52-week high and low of DRREDDY?
High ₹1,414.90 on 29 Jun 2026, low ₹1,101.00 on 23 Jul 2026 (adjusted for bonuses and splits).
What is the dividend yield of DRREDDY?
0.58%: dividends of ₹8.00 per share with ex-dates in the last 12 months, divided by the latest price.
What return has DRREDDY given?
1 year +14.5%, 3 years +30.5%, 5 years +44.1% (price only, dividends not included).
Which sector is DRREDDY in?
NSE classifies Dr. Reddy's Laboratories Ltd. under Healthcare. Other Nifty 50 companies in it: APOLLOHOSP, CIPLA, MAXHEALTH, SUNPHARMA.
Who owns DRREDDY?
On 30 Sep 2026, promoters held 26.63% and the public 73.17%.
How can I buy DRREDDY shares?
Through a SEBI-registered stockbroker with a demat and trading account. stockER is an information site only: it doesn't sell shares or recommend buying or selling any of them.